Xyzal given FDA approval for use in children as young as six months
스크롤 이동 상태바
Xyzal given FDA approval for use in children as young as six months
기자명
메디칼라이터팀
입력 2009.08.26 00:00
수정 2009.08.26 10:09
댓글 0
Sanofi-Aventis SA and Belgian biotech drugmaker UCB"s once-daily allergy medication Xyzal [levocetirizine dihydrochloride], has received FDA approval for children as young as six months. It has been approved to treat indoor allergies and hives in children six months and older as well as for outdoor allergies in children older than two.